Ok I’ll address your misinformation/lack of information.“What...

Ok I’ll address your misinformation/lack of information.

“What are you talking about, your suggesting investing in a company where their lead drug is a Herb/ Plant (EBC-46 aka Hylandia dockrillii)- which I can't find any pair reviewed studies/ journal reports to back up the company's claims.”

You don’t even know the plant species. You can’t find peer reviewed studies because we are not yet in phase I trials. Pretty simple really.


“What acquisitions are you referring to? This company looks like the biggest piece of hot air I've seen for awhile. Looks at the Directors, there's not even one Biochemist directly involved, nor is there anyone with Oncology/ industry experience- just a bunch of veterinary specialists by the looks of it.
For the record there's never been an Aussie biotech that's been acquired for big $$ by a US pharma during a Phase 1/2a oncology study. In fact there's never been one acquired full stop. Let alone one that's lead compound is based off a plant found in" the tropical rainforests of North Queensland". Sounds like a patient nightmare.”

Never been Aussie biotech acquired by big pharma? Did you ever hear of a company called Peplin? Did you know how insignificant their lead compound is when stacked up against EBC-46? Would you not call US $287m big money? LEO Pharma isn’t big enough? Recent acquisitions? Have a read of the following…

Company Stage $US in millions
Forma Therapeutics discovery 815
Aveopharma pre-clinical 555
Argale ph 1 265
Array biopharma ph 1 713
Clovis ph 1 262
Pharmacyclis ph 2 975
Endocyte ph 3 1,000

Oh and experience?...
Dr Victoria Gordon
Dr Rodney Cusack
Dr Peter Schmidt
Dr Peter Parsons


“Look at the likes of Alchmeia( ASX:ACL), their M…..”

EBC-46 is a completely new novel compound. It is not some off patent generic drug which has been slightly tweaked to slightly improve it. This is why the feedback from the FDA has been very positive and hints at fast tracking trials a possibility. The FDA usually see crap like Alchemia where miniscule tweaking of an already known drug is the companies only lead compound.

“Are you currently invested in any Oncology company's? Particularly those on the ASX? Do you know what big Pharma look for when they acquire early stage company's?”

Yes. Yes. Yes.


“I think your the one living under the rock here. This company will keep sucking investors dry for years. There's red flags all over it- go ask anyone who specializes in biotech's.”

I’ve deduced you’re under a rock my friend.